Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

IDEXX Laboratories reports increased revenues for 2009 third quarter

IDEXX Laboratories, Inc., today reported that revenues for the third quarter of 2009 were $259.1 million compared to $251.1 million for the third quarter of 2008.

23 Oct 2009

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in an international Phase 3 trial to evaluate Nexavar® (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer.

23 Oct 2009

Dig Pink Volleyball Breast Cancer Awareness campaign to raise $1 million in support of breast cancer research

The Side-Out Foundation and its Dig Pink- Volleyball Breast Cancer Awareness campaign will launch a first of its kind clinical trial this month to examine the effects of individualized treatment on patients with metastatic breast cancer.

23 Oct 2009

TargeGen completes JAK2 inhibitor TG101348 clinical trial in myelofibrosis patients

TargeGen, Inc. today announced that the Company has successfully completed a 59 patient, multicenter clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myelofibrosis.

23 Oct 2009

Bioidentical Hormones for breast cancer prevention

For a sample of prevention awareness on Breast Cancer and overall health, there are key terms one is suggested to start on: BRCA; DHEA; Estradiol; Estriol; Free radicals; Insulin resistance; Melatonin; Premarin; Progesterone; SHBG; vitamin D.

22 Oct 2009

New tools needed to identify men and women at risk for the most aggressive cancers

Twenty years of screening for breast and prostate cancer - the most diagnosed cancer for women and men - have not brought the anticipated decline in deaths from these diseases, argue experts from the University of California, San Francisco and the University of Texas Health Science Center at San Antonio in an opinion piece published in the "Journal of the American Medical Association."

21 Oct 2009

Report: National investment on childhood and adolescent cancer research

The first-ever detailed examination of a country's investment in research on childhood and adolescent cancers was released today by the Canadian Cancer Research Alliance (CCRA) and the Canadian Partnership Against Cancer (the Partnership).

20 Oct 2009

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Novartis announced today that Tasigna (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna was well tolerated in the study.

20 Oct 2009

Article evaluating StemEx therapy for leukemia and lymphoma to be published

Gamida Cell announced today the publication of an article evaluating carlecortemcel-l, the generic name of what is widely known as "StemEx", as a therapy for blood cancers such as leukemia and lymphoma.

19 Oct 2009

IL-2 compound ineffective against HIV-AIDS

An international research team has demonstrated that treating HIV-AIDS with interleukin-2 (IL-2) is ineffective. As a result, the researchers recommend that clinical trials on this compound be stopped.

19 Oct 2009

New chromosomal abnormality in acute lymphoblastic leukemia

Researchers identified a new chromosomal abnormality in acute lymphoblastic leukemia (ALL) that appears to work in concert with another mutation to give rise to cancer. This latest anomaly is particularly common in children with Down syndrome.

19 Oct 2009

FDA grants marketing approval for Elitek

Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Elitek (rasburicase) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid.

19 Oct 2009

Managing Myeloma website offers scholarship for attending the December 2009 American Society of Hematology Annual Meeting

Managing Myeloma (www.ManagingMyeloma.com), an accredited multi-supported educational website for multidisciplinary professionals, announces the opportunity for fellows in oncology to win a scholarship to attend the December 2009 American Society of Hematology Annual Meeting in New Orleans, Louisiana. The scholarship includes registration fees, airfare, hotel accommodations, and a per diem for meals.

15 Oct 2009

North Bend Medical Centers partners with Oracle and PracticeOne to support its medical specialties

North Bend Medical Centers of Coos Bay, Oregon, a 55-physician, 300+ employee, multi-specialty clinic and provider to over 60,000 patients, is an innovative user of healthcare information technology. The clinic is comprised of five locations across southern Oregon and represents 15 medical specialties and has partnered closely with PracticeOne and Oracle as key technology providers to support its doctors and clinics.

13 Oct 2009

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

Celator Pharmaceuticals today announced that it has completed enrollment in its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML).

12 Oct 2009

Bio-Matrix Scientific Group provides updates on COPD research

Bio-Matrix Scientific Group, Inc. provided a progress report on the Company’s previously announced new opportunities. The Company has been moving forward in the areas of stem cell research for treatment of Chronic Obstructive Pulmonary Disease (COPD), Tumor Banking and Cancer Treatment.

12 Oct 2009

2009 ASH Visitor Training Program to build hematologic capacity in developing countries

The American Society of Hematology (ASH) is proud to announce the participants in the 2009 ASH Visitor Training Program, which builds hematologic capacity in developing countries. Through this program, hematologists and medical professionals from developing countries receive valuable clinical, laboratory, or technological training on a specific topic at a host institution under the mentorship of an ASH member anywhere in the world.

12 Oct 2009

Hematology News and Research

Further Reading

IDEXX Laboratories reports increased revenues for 2009 third quarter

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Dig Pink Volleyball Breast Cancer Awareness campaign to raise $1 million in support of breast cancer research

TargeGen completes JAK2 inhibitor TG101348 clinical trial in myelofibrosis patients

Bioidentical Hormones for breast cancer prevention

New tools needed to identify men and women at risk for the most aggressive cancers

Report: National investment on childhood and adolescent cancer research

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Article evaluating StemEx therapy for leukemia and lymphoma to be published

IL-2 compound ineffective against HIV-AIDS

New chromosomal abnormality in acute lymphoblastic leukemia

FDA grants marketing approval for Elitek

Managing Myeloma website offers scholarship for attending the December 2009 American Society of Hematology Annual Meeting

North Bend Medical Centers partners with Oracle and PracticeOne to support its medical specialties

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

Bio-Matrix Scientific Group provides updates on COPD research

2009 ASH Visitor Training Program to build hematologic capacity in developing countries

NIH awards Beth Israel Deaconess Medical Center $38.2M in grants

New soy germ-based ingredient improves menopausal symptoms

HST Global announces alliance for R&D of Nutraceutical and Medical Food formulation platform

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News